secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zomedica Corp. (ZOMDF)
CIK:        0001684144
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0001654954-23-010493
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zomedica Q2 revenue up 43% to $6.0M; net loss flat at $5.3M; cash $142.4M
-------------------------------------------------------------------------

- Revenue $6.0M vs $4.2M YoY (+43%); therapeutic segment $5.8M (+38%), diagnostic $0.2M (+100%).
- Net loss $5.3M ($0.005/sh) unchanged YoY; adjusted non-GAAP EBITDA loss $3.1M.
- Cash & equivalents $142.4M, down from $186.8M YoY; normalized operating burn ~$3M.
- Gross margin 67%; adjusted >70% excluding one-time costs; consumable revenue $4.0M (+48% YoY).
- Due diligence on potential SMP (VetGuardian) acquisition progressing; TRUVIEW digital microscopy launched late June.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1684144/000165495423010493/0001654954-23-010493-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1684144/000165495423010493/zom_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-23-010493

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer